Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
Leukemia|April 5, 2014
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II studyS E M Herman, C U Niemann, M Farooqui, et al.Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2015
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyCarsten U Niemann, Sarah E M Herman, Irina Maric, et al.Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.Leukemia & Lymphoma|March 11, 2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemiaFie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, et al.Pageof 10